25-April-2019: The global spinal muscular
atrophy (SMA) treatment market size is expected to reach USD 3.9 billion by
2025, according to a new report by Grand View Research, Inc. It is estimated to
register a CAGR of 12.9% during the forecast period. Due to the rare nature and
complexity of these diseases, scientific knowledge pertaining to them is
scarce. However, there are various initiatives undertaken to increase awareness
regarding rare diseases and to support SMA communities. This is anticipated to
boost the market development over the coming years.
Various SMA communities and
companies have collaborated for developing disease treatment therapy. For
example, RG7916, which is an investigational therapy being developed by Roche
in collaboration with SMA Foundation and PTC Therapeutics. Thus, heavy
investments in R&D by major companies are also projected to contribute
toward the growth of this market. CureSMA, SMA Foundation, and SMA Europe are
some of the organizations actively supporting R&D pertaining to SMA.
CureSMA provided funding to a
research project to Biogen and Ionis Pharmaceuticals, Inc. for developing
Spinraza, which received U.S. FDA approval in 2016. This organization has
invested nearly USD 70 million in the research pertaining to SMA, which also
included a planned investment of USD 5 million in the coming years.
In
depth research report on Spinal Muscular Atrophy (SMA) Treatment Market
Further
key findings from the study suggest:
· The
global spinal muscular atrophy treatment market is projected to expand at a
CAGR of 12.9% over the forecast period
· Based
on disease type, type 1 accounted for the largest revenue share owing to rising
incidence of type 1 SMA
· By
treatment, the drug segment accounted for the largest revenue share in 2017
· North
America will retain its lead as the largest regional market; however Asia
Pacific is anticipated to register the fastest CAGR over the forecast period
· Themarket
is presently led by Biogen Inc. Biogen’s Spinraza is the only approved
commercialized treatment for SMA, owing to which market is not competitive.
However, this trend is expected to change after the commercialization of other
treatment therapies post 2020
Grand View Research has
segmented the global spinal muscular atrophy treatment market on the basis of
disease type, treatment, route of administration, and region:
SMA
Treatment Disease Type Outlook (Revenue, USD Million, 2015 - 2025)
· Type 1
· Type 2
· Type 3
· Type 4
SMA
Treatment Outlook (Revenue, USD Million, 2015 - 2025)
· Gene
Therapy
· Drug
· Spinraza
· RG6083
(Olesoxime)
· RG7916
SMA
Treatment Route of Administration Outlook (Revenue, USD Million, 2015 - 2025)
· Oral
· Intrathecal
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment